BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30338649)

  • 21. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept.
    Generali E; Carrara G; Kallikourdis M; Condorelli G; Bortoluzzi A; Scirè CA; Selmi C
    Rheumatol Int; 2019 Feb; 39(2):239-243. PubMed ID: 30413926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Leu JH; Adedokun OJ; Gargano C; Hsia EC; Xu Z; Shankar G
    Rheumatology (Oxford); 2019 Mar; 58(3):441-446. PubMed ID: 30412238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
    Feagan BG; Lam G; Ma C; Lichtenstein GR
    Aliment Pharmacol Ther; 2019 Jan; 49(1):31-40. PubMed ID: 30411382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs.
    Hewlett S; Haig-Ferguson A; Rose-Parfitt E; Halls S; Freke S; Creamer P
    Musculoskeletal Care; 2019 Mar; 17(1):63-71. PubMed ID: 30398699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upadacitinib for the treatment of rheumatoid arthritis.
    Serhal L; Edwards CJ
    Expert Rev Clin Immunol; 2019 Jan; 15(1):13-25. PubMed ID: 30394138
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease.
    Klenske E; Osaba L; Nagore D; Rath T; Neurath MF; Atreya R
    J Crohns Colitis; 2019 Feb; 13(2):267-269. PubMed ID: 30388211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.
    Hu C; Adedokun OJ; Zhang L; Sharma A; Zhou H
    J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):803-816. PubMed ID: 30377888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.
    Lin PT; Wang SH; Chi CC
    Sci Rep; 2018 Oct; 8(1):16068. PubMed ID: 30375427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report.
    Ciccullo A; Ponziani FR; Maiolo E; Pallavicini F; Pompili M
    Infection; 2019 Apr; 47(2):313-316. PubMed ID: 30368733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
    Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
    Arthritis Res Ther; 2019 Nov; 21(1):255. PubMed ID: 31779676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
    Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
    Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.
    Bonafede MMK; McMorrow D; Proudfoot C; Shinde S; Kuznik A; Chen CI
    Am Health Drug Benefits; 2018 Jun; 11(4):192-202. PubMed ID: 30464787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apixaban for stroke prevention in a patient with a mechanical heart valve.
    Shukla P; Ashraf I; Aghoram P
    Br J Hosp Med (Lond); 2018 Nov; 79(11):652-653. PubMed ID: 30418836
    [No Abstract]   [Full Text] [Related]  

  • 35. Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy.
    Cerda OL; de Los Angeles Correa M; Granel A; Marcos AI; Giraldo C; Rillo O; Schneeberger EE; Citera G
    Eur J Rheumatol; 2019 Jan; 6(1):19-22. PubMed ID: 30407165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data.
    Üsküdar Cansu D; Üsküdar Teke H; Temel T; Ertürk A; Kahraman O; Korkmaz C
    J Natl Med Assoc; 2019 Jun; 111(3):262-269. PubMed ID: 30389147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study.
    van Bentum RE; Heslinga SC; Nurmohamed MT; Gerards AH; Griep EN; Koehorst CBJM; Kok MR; Schilder AM; Verhoef M; van der Horst-Bruinsma IE
    J Rheumatol; 2019 Feb; 46(2):153-159. PubMed ID: 30385705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study.
    Tien YC; Yen HH; Li CF; Liu MP; Hsue YT; Hung MH; Chiu YM
    Arthritis Res Ther; 2018 Nov; 20(1):246. PubMed ID: 30382902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids.
    van Vollenhoven R; Helt C; Arora V; Zhong J; Correia AP; de la Torre I; Muram D
    Rheumatol Ther; 2018 Dec; 5(2):525-536. PubMed ID: 30357613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect.
    Germain V; Scherlinger M; Barnetche T; Schaeverbeke T;
    Ann Rheum Dis; 2020 Jan; 79(1):e11. PubMed ID: 30352888
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.